Based on genetic approaches establishing a tumor-permissive phenotype using CHRNA7KO mice (Fig. 1), we next tested a pharmacological approach that focused on in vivo testing of a small molecule agonist that is highly specific for CHRNA7, AR-R17779, in several different models of TNBC (Fig. 5). This evidence concerns the gene AR and neoplasm.